Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DSGN · against 484 other Healthcare companies of similar size
Ranked #317 of 485 · scores higher than 12% of peers
Bars: peers in each 10-point band of the valuation score169 peers with a valuation score of 0–9, including DSGN · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | DSGN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 473 reported | -11.4% | 0.7% | 18% | 30% | |
| EBITDA yieldHigher is better · 489 reported | -17.7% | 3.6% | 11% | 50% | |
| Free cash flow yieldHigher is better · 204 reported | -8.5% | -4.2% | 38% | 20% | |
| Book yieldHigher is better · 483 reported | 31.2% | 45.6% | 30% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 317 | 357M USD | 8 | 32 | |
| 317 | 635M USD | 8 | 39 | |
| 317 | 539M USD | 8 | 33 | |
| 317 | 1.3B USD | 8 | 30 | |
| 317 | 647M USD | 8 | 40 | |
| 317 | 399M USD | 8 | 32 | |
| 317 | 4.6B SEK (≈$462M) | 8 | 37 | |
| 317 | 530M USD | 8 | 23 | |
| 317 | 487M USD | 8 | 29 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score